Century Therapeutics (IPSC)

• Market cap: $417M
• 1 day: 0.87%
• 5 days: 3.59%
• 1 month: 5.48%
• 3 months: 25.54%
• 6 months: 285%
• Year to date: 132.18%
• 1 year: 315.92%
• 5 years: -89.88%
• 10 years: -89.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Employees: 78